Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Ikena Oncology stock
Learn how to easily invest in Ikena Oncology stock.
Ikena Oncology Inc is a biotechnology business based in the US. Ikena Oncology shares (IKNA) are listed on the NASDAQ and all prices are listed in US Dollars. Ikena Oncology employs 67 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Ikena Oncology
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IKNA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Ikena Oncology stock price (NASDAQ: IKNA)Use our graph to track the performance of IKNA stocks over time.
Ikena Oncology shares at a glance
|Latest market close||$4.20|
|52-week range||$2.83 - $17.60|
|50-day moving average||$4.07|
|200-day moving average||$9.22|
|Wall St. target price||$24.33|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.78|
Buy Ikena Oncology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Ikena Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Ikena Oncology price performance over time
|1 week (2022-06-28)||-10.64%|
|1 month (2022-06-06)||17.65%|
|3 months (2022-04-06)||-24.60%|
|6 months (2022-01-06)||-65.46%|
|1 year (2021-07-06)||-67.79%|
|2 years (2020-07-02)||N/A|
|3 years (2019-07-02)||N/A|
|5 years (2017-07-02)||N/A|
Is Ikena Oncology stock undervalued or overvalued?
Valuing Ikena Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ikena Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ikena Oncology's P/E ratio
Ikena Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Ikena Oncology shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Ikena Oncology's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Ikena Oncology financials
|Revenue TTM||$30.9 million|
|Gross profit TTM||$-16,123,000|
|Return on assets TTM||-9.92%|
|Return on equity TTM||-19.61%|
|Market capitalisation||$170.6 million|
TTM: trailing 12 months
Ikena Oncology share dividends
We're not expecting Ikena Oncology to pay a dividend over the next 12 months.
Ikena Oncology overview
Ikena Oncology, Inc. , a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. .
Ikena Oncology in the news
Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
Frequently asked questionsWhat percentage of Ikena Oncology is owned by insiders or institutions?
Currently 0.401% of Ikena Oncology shares are held by insiders and 93.442% by institutions. How many people work for Ikena Oncology?
Latest data suggests 67 work at Ikena Oncology. When does the fiscal year end for Ikena Oncology?
Ikena Oncology's fiscal year ends in December. Where is Ikena Oncology based?
Ikena Oncology's address is: 645 Summer Street, Boston, MA, United States, 02210 What is Ikena Oncology's ISIN number?
Ikena Oncology's international securities identification number is: US45175G1085
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert